A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Trial Status: Active
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Inclusion Criteria
- Advanced Renal Cell Carcinoma
- Must have at least 1 lesion with measurable disease
- Life expectancy of at least 3 months
- Karnofsky Performance Status (KPS) must be =>70%
Exclusion Criteria
- Patients/subjects with suspected or known central nervous system metastases unless adequately treated
- Patients/subjects with autoimmune disease
- Patients/subjects who need daily oxygen therapy
Connecticut
New Haven
Yale University
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Maryland
Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE
Massachusetts
Boston
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
Massachusetts General Hospital Cancer Center
Status: ACTIVE
Michigan
Detroit
Wayne State University / Karmanos Cancer Institute
Status: CLOSED_TO_ACCRUAL
Missouri
Saint Louis
Siteman Cancer Center at Washington University
Status: CLOSED_TO_ACCRUAL
New York
Buffalo
Roswell Park Cancer Institute
Status: ACTIVE
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: ADMINISTRATIVELY_COMPLETE
Ohio
Columbus
Ohio State University Comprehensive Cancer Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Oregon
Portland
OHSU Knight Cancer Institute
Status: ACTIVE
South Carolina
Charleston
Medical University of South Carolina
Status: COMPLETED
Texas
Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: ACTIVE
Contact: Marcella West Aguilar
Phone: 214-648-1479
Virginia
Charlottesville
University of Virginia Cancer Center
Status: ACTIVE
Washington
Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Trial Phase Phase II
Trial Type Treatment
Lead Organization
Bristol-Myers Squibb
- Primary ID CA018-005
- Secondary IDs NCI-2017-00404, 2016-003082-26
- Clinicaltrials.gov ID NCT02996110